MWNA
OTLKW

Marshall Wace North America’s Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 OTLKW Stock Holding History

Marshall Wace North America’s Portfolio OTLKW Stock Details OTLKW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$272K Hold
125,400
– – ﹤0.01% 1273
2021
Q2 		$312K Hold
125,400
– – ﹤0.01% 1276
2021
Q1 		$282K Hold
125,400
– – ﹤0.01% 1325
2020
Q4 		$163K Buy
+125,400
New +$20.9K ﹤0.01% 1246

Other funds holding OTLKW

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace North America's OTLKW Position: Q4 2020 in Review

Marshall Wace North America sold out of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) in Q4 2020, closing a stake of 125,400 shares — an estimated $20.9K sold.

Marshall Wace North America first reported a position in OTLKW in Q4 2018 and held it in 8 quarters. The position peaked at $45K in Q1 2019. 4 funds tracked by Wall St. Rank hold OTLKW as of Q4 2020.

  • Marshall Wace North America reported no remaining Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 125,400 Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 shares in Q4 2020, an estimated $20.9K.
  • Marshall Wace North America first reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in Q4 2018 and held it in 8 quarters.
  • Marshall Wace North America's Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position peaked at $45K in Q1 2019.
  • 4 funds tracked by Wall St. Rank held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.